ABSTRACT:
BACKGROUND: Several
studies have suggested a cancer risk reduction in statin users although the
evidence remains weak for stomach cancer. The purpose of this study was to use
an exact-matching case--control design to examine the risk of gastric cancer
associated with the use of statins in a cohort of patients with diabetes.
METHODS:
Cases were defined as
patients with incident gastric cancer identified by International
Classification of Diseases 16.0 ~ 16.9 recorded at Samsung Medical Center
database during the period of 1999 to 2008, at least 6 months after the entry
date of diabetes code. Each gastric cancer case patient was matched with one
control patient from the diabetes patient registry in a 1:1 fashion, blinded to
patient outcomes.
RESULTS:
A total of 983 cases
with gastric cancer and 983 controls without gastric cancer, matched by age and
sex, were included in the analysis. The presence of prescription for any statin
was inversely associated with gastric cancer risk in the unadjusted conditional
logistic regression model (OR: 0.18; 95% CI: 0.14 -- 0.24; P < .0001).
Multivariate analysis using conditional logistic regression with Bonferroni's
correction against aspirin indicated a significant reduction in the risk of
gastric cancer in diabetes patients with statin prescriptions (OR: 0.21; 95%
CI: 0.16 -- 0.28; P < .0001). After adjustment for aspirin use, a longer
duration of statin use was associated with reduced risk of gastric cancer, with
statistical significance (P<.0001).
CONCLUSIONS:
A strong inverse
association was found between the risk of gastric adenocarcinoma and statin use
in diabetic patients.
Source: Statins
and the risk of gastric cancer in diabetes patients. Lee J, Lee SH, Hur KY, Woo
SY, Kim SW, Kang WK (wkkang@skku.edu). BMC
Cancer. 2012 Dec 13;12(1):596.
Free paper available at:
Aucun commentaire:
Enregistrer un commentaire